MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us

Tagged fingolimod

Vitamin B12

Is Vitamin B12 Important in Multiple Sclerosis?

MStranslate
December 20, 2023
Fingolimod, Research, Vitamin B12
2 Comments
Research Summary: FTY720 requires vitamin B12-TCN2-CD320 signaling in astrocytes to reduce disease in an animal model of multiple sclerosis The...
MOMENTUM

MOMENTUM Phase II Trial Results

MStranslate
August 22, 2016
Clinical Trials, Fingolimod, Research
The background Fingolimod was approved in 2010 and became the first oral drug for the treatment of relapsing-remitting MS (RRMS).  It has proven to...
Rituximab

Rituximab vs Fingolimod in JCV+ Individuals

MStranslate
April 5, 2016
Fingolimod, Natalizumab, Research, Rituximab
Research Summary: Rituximab versus fingolimod after natalizumab in multiple sclerosis patients The background Whilst natalizumab has emerged as...

Recent Posts

  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026

Recent Comments

  • MStranslate on Multiple Sclerosis Research In 2026
  • MStranslate on Multiple Sclerosis Research In 2026
  • K on Multiple Sclerosis Research In 2026
  • Mohammad on Multiple Sclerosis Research In 2026
  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date

Calendar

August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
« Jul    

Archives

Categories

Posts

  • Potential Changes to MS Treatment Access in Australia
  • MS Auckland Webinar: AHSCT as a Treatment for MS
  • MS Auckland Webinar: Remyelination Research in MS
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.